Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to VEGF Inhibition in nAMD Within a Clinical Trial Setting (M-VIVA)

NCT07249216 NA RECRUITING

Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40% have a suboptimal response. In this study, the investigators want to identify other factors (beyond VEGF) that might be driving the disease in these non-responding patients. By looking at samples from inside the eye (vitreous humor) and comparing "good responders" to "suboptimal responders", the investigators hope to find potential new treatment approaches or biomarkers for nAMD.

Details

Lead sponsor	Singapore National Eye Centre
Phase	NA
Status	RECRUITING
Enrolment	117
Start date	2025-07-18
Completion	2029-07

Conditions

• Age Related Macular Degeneration

Interventions

• Faricimab
• Ranibizumab

Primary outcomes

• Difference in vitreous biomarker concentrations between responders and non-responders — 24 weeks
  Comparison of inflammatory and angiogenic biomarkers in vitreous humor measured at baseline, week 12, and week 24

Countries

Singapore